Your browser doesn't support javascript.
loading
Prostate Cancer Survival and Mortality according to a 13-year retrospective cohort study in Brazil: Competing-Risk Analysis / Sobrevida e mortalidade por câncer da próstata no Brasil por 13 anos em um estudo de coorte retrospectivo: Análise de riscos competitivos
Faculty of MedicineBraga, Sonia Faria Mendes; Department of Epidemiology and BiostatisticsSilva, Rumenick Pereira da; Faculty of PharmacyGuerra Junior, Augusto Afonso; Faculty of MedicineCherchiglia, Mariangela Leal.
  • Faculty of MedicineBraga, Sonia Faria Mendes; Universidade Federal de Minas Gerais. Graduate Program in Public Health. Faculty of MedicineBraga, Sonia Faria Mendes. Belo Horizonte. BR
  • Department of Epidemiology and BiostatisticsSilva, Rumenick Pereira da; Universidade Federal Fluminense. Faculty of Medicine. Department of Epidemiology and BiostatisticsSilva, Rumenick Pereira da. Niterói. BR
  • Faculty of PharmacyGuerra Junior, Augusto Afonso; Universidade Federal de Minas Gerais. Graduate Program in Medicines and Pharmaceutical Assistance. Faculty of PharmacyGuerra Junior, Augusto Afonso. Belo Horizonte. BR
  • Faculty of MedicineCherchiglia, Mariangela Leal; Universidade Federal de Minas Gerais. Graduate Program in Public Health. Faculty of MedicineCherchiglia, Mariangela Leal. Belo Horizonte. BR
Rev. bras. epidemiol ; 24: e210006, 2021. tab, graf
Article in English | LILACS | ID: biblio-1156017
ABSTRACT
ABSTRACT

Objective:

To analyze cancer-specific mortality (CSM) and other-cause mortality (OCM) among patients with prostate cancer that initiated treatment in the Brazilian Unified Health System (SUS), between 2002 and 2010, in Brazil.

Methods:

Retrospective observational study that used the National Oncological Database, which was developed by record-linkage techniques used to integrate data from SUS Information Systems, namely Outpatient (SIA-SUS), Hospital (SIH-SUS), and Mortality (SIM-SUS). Cancer-specific and other-cause survival probabilities were estimated by the time elapsed between the date of the first treatment until the patients' deaths or the end of the study, from 2002 until 2015. The Fine-Gray model for competing risk was used to estimate factors associated with patients' risk of death.

Results:

Of the 112,856 studied patients, the average age was 70.5 years, 21% died due to prostate cancer, and 25% due to other causes. Specific survival in 160 months was 75%, and other-cause survival was 67%. For CSM, the main factors associated with patients' risk of death were stage IV (AHR = 2.91; 95%CI 2.73 - 3.11), systemic treatment (AHR = 2.10; 95%CI 2.00 - 2.22), and combined surgery (AHR = 2.30, 95%CI 2.18 - 2.42). As for OCM, the main factors associated with patients' risk of death were age and comorbidities.

Conclusion:

The analyzed patients with prostate cancer were older and died mainly from other causes, probably due to the presence of comorbidities associated with the tumor.
RESUMO
RESUMO

Objetivo:

Analisar a mortalidade câncer-específica (MCE) e a mortalidade por outras causas (MOC) em pacientes diagnosticados com câncer da próstata que iniciaram tratamento no Sistema Único de Saúde (SUS) entre 2002 e 2010, no Brasil.

Métodos:

Estudo observacional retrospectivo utilizando a "Base Nacional em Oncologia", desenvolvida por meio de pareamento determinístico-probabilístico dos sistemas de informação do SUS Ambulatorial (SIA), Hospitalar (SIH) e de Mortalidade (SIM). Probabilidades de sobrevivência específicas do câncer e por outras causas foram estimadas pelo tempo decorrido entre a data do primeiro tratamento até a morte do paciente ou o final do estudo, de 2002 a 2015. O modelo de riscos competitivos de Fine & Gray foi utilizado para estimar os fatores associados ao risco de morte do paciente.

Resultados:

Dos 112.856 pacientes estudados, a idade média foi de 70,5 anos, 21% foi a óbito devido ao câncer de próstata e 25% por outras causas. A probabilidade de sobrevida específica em160 meses foi de 75% e a por outras causas de 67%. Na CSM, os principais fatores associados ao risco de óbito dos pacientes foram estágio IV (AHR = 2,91; IC95% 2,73 - 311), tratamento sistêmico (AHR = 2,10; IC95% 2,00 - 2,22) e cirurgia combinada (AHR = 2,30; IC95% 2,18 - 2,42). Na MOC, os principais fatores associados ao risco de óbito do paciente foram idade e comorbidades.

Conclusão:

Os pacientes com câncer da próstata analisados mostraram-se mais velhos e faleceram principalmente por outras causas, provavelmente devido às comorbidades associadas ao tumor.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Prostatic Neoplasms Type of study: Etiology study / Observational study / Prognostic study / Risk factors Limits: Aged / Humans / Male Country/Region as subject: South America / Brazil Language: English Journal: Rev. bras. epidemiol Journal subject: Epidemiology / Public Health Year: 2021 Type: Article Affiliation country: Brazil Institution/Affiliation country: Universidade Federal Fluminense/BR / Universidade Federal de Minas Gerais/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Prostatic Neoplasms Type of study: Etiology study / Observational study / Prognostic study / Risk factors Limits: Aged / Humans / Male Country/Region as subject: South America / Brazil Language: English Journal: Rev. bras. epidemiol Journal subject: Epidemiology / Public Health Year: 2021 Type: Article Affiliation country: Brazil Institution/Affiliation country: Universidade Federal Fluminense/BR / Universidade Federal de Minas Gerais/BR